acquired aneurysmal subarachnoid hemorrhage
ORPHA: 900651 Treatment Available
Overview
human disease
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| nimodipine | oral capsule 30mg; oral solution 30mg/10mL | FDA Approved, EMA Approved | 8 | 5d |
Clinical Presentation
Signs and symptoms associated with acquired aneurysmal subarachnoid hemorrhage, sourced from HPO and Orphanet clinical annotations.
Abnormal cerebral artery morphologyHypertensionConstriction of peripheral visual fieldComaCerebral hemorrhageVomitingNauseaHeadacheMemory impairmentST segment depressionVasospasmCognitive impairmentHydrocephalusVisual impairmentHypothyroidismSeizureSyncopeCongestive heart failureMyocardial infarctionLeft ventricular hypertrophyIncreased total leukocyte countIschemic strokeProgressive neurologic deteriorationIncreased CSF lactateCerebral ischemiaHyperglycemiaHypercholesterolemiaFunctional motor deficitProlonged QTc intervalCranial nerve paralysisAddictive alcohol useImpairment of activities of daily livingHyperglycorrhachiaHypopituitarism
Classification & Codes
Orphanet Code
ORPHA:90065acquired aneurysmal subarachnoid hemorrhage
| Orphanet | ORPHA:90065 |
| Treatments | 1 drug(s) |
| Symptoms on record | 34 signs |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO